awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q55101776-16C20C9A-613D-4441-9756-893E367D6D82
Q55101776-16C20C9A-613D-4441-9756-893E367D6D82
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55101776-16C20C9A-613D-4441-9756-893E367D6D82
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.
P2860
Q55101776-16C20C9A-613D-4441-9756-893E367D6D82
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55101776-16C20C9A-613D-4441-9756-893E367D6D82
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
61934c33369645a9797bea86f72779136d6b4499
P2860
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.